Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12158808 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL4667082 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL12158787 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14301399 | 0.92 | ADRB2 (0.55) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14300964 | 0.92 | ADRB2 (0.55) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL11747826 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178271 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178277 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178269 | 0.85 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178341 | 0.85 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391866-A1 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-11-28 | — | — | US | claimed |
| EP-4402120-A1 | PROCESS FOR THE PREPARATION OF A SALBUTAMOL INTERMEDIATE | Yeda Research and Development Co. Ltd (IL) | 2024-07-24 | — | — | EP | claimed |
| CN-113668271-B | High-bulk gray board paper and preparation method thereof | 浙江金龙再生资源科技股份有限公司 | 2023-08-11 | — | — | CN | claimed |
| WO-2023062633-A1 | PROCESS FOR THE PREPARATION OF A SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-20 | — | — | WO | claimed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| US-20240391866-A1 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-11-28 | — | — | US | disclosed |
| US-20240391866-A1 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-11-28 | — | — | US | disclosed |
| CN-118724796-A | Phenylpropionic acid derivative, and preparation method and application thereof | 广东众生睿创生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118619932-A | GPR40 agonist and preparation method and application thereof | 广东众生睿创生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4416146-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-C] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | Lomond Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4402120-A1 | PROCESS FOR THE PREPARATION OF A SALBUTAMOL INTERMEDIATE | Yeda Research and Development Co. Ltd (IL) | 2024-07-24 | — | — | EP | disclosed |
| CN-117263952-A | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-111836814-B | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-113668271-B | High-bulk gray board paper and preparation method thereof | 浙江金龙再生资源科技股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-113668271-B | High-bulk gray board paper and preparation method thereof | 浙江金龙再生资源科技股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023062633-A1 | PROCESS FOR THE PREPARATION OF A SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023062633-A1 | PROCESS FOR THE PREPARATION OF A SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064133-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-109311809-B | Cationic lipids | 卫材R&D管理有限公司 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391866-A1 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | ADRB3, ADH1C, ADRB2 | ADRB2 3/4885ADRB1 4/4885CYP1A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.